B1SX34 Stock Overview
Develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. More details
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 4/6 |
| Past Performance | 4/6 |
| Financial Health | 5/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
No risks detected for B1SX34 from our risk checks.
Boston Scientific Corporation Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$519.48 |
| 52 Week High | US$522.00 |
| 52 Week Low | US$267.84 |
| Beta | 0.80 |
| 11 Month Change | 3.43% |
| 3 Month Change | 20.33% |
| 1 Year Change | 92.66% |
| 33 Year Change | 129.74% |
| 5 Year Change | n/a |
| Change since IPO | 187.60% |
Recent News & Updates
Recent updates
Shareholder Returns
| B1SX34 | BR Medical Equipment | BR Market | |
|---|---|---|---|
| 7D | 1.4% | -1.6% | -0.4% |
| 1Y | 92.7% | 16.0% | -2.2% |
Return vs Industry: B1SX34 exceeded the BR Medical Equipment industry which returned 16% over the past year.
Return vs Market: B1SX34 exceeded the BR Market which returned -2.2% over the past year.
Price Volatility
| B1SX34 volatility | |
|---|---|
| B1SX34 Average Weekly Movement | 2.7% |
| Medical Equipment Industry Average Movement | 7.1% |
| Market Average Movement | 4.4% |
| 10% most volatile stocks in BR Market | 8.5% |
| 10% least volatile stocks in BR Market | 2.2% |
Stable Share Price: B1SX34 has not had significant price volatility in the past 3 months compared to the BR market.
Volatility Over Time: B1SX34's weekly volatility (3%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1979 | 48,000 | Mike Mahoney | www.bostonscientific.com |
Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through two segments, MedSurg and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions, such as resolution clips, biliary stent systems, stents and electrocautery enhanced delivery systems, direct visualization systems, digital catheters, and single-use duodenoscopes; devices to treat urological conditions, including ureteral stents, catheters, baskets, guidewires, sheaths, balloons, single-use digital flexible ureteroscopes, holmium laser systems, artificial urinary sphincter, laser system, fiber, and hydrogel systems; and devices to treat neurological movement disorders and manage chronic pain, such as spinal cord stimulator system, proprietary programming software, radiofrequency generator, indirect decompression systems, practice optimization tools, and deep brain stimulation system.
Boston Scientific Corporation Fundamentals Summary
| B1SX34 fundamental statistics | |
|---|---|
| Market cap | R$769.53b |
| Earnings (TTM) | R$10.35b |
| Revenue (TTM) | R$91.85b |
74.3x
P/E Ratio8.4x
P/S RatioIs B1SX34 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| B1SX34 income statement (TTM) | |
|---|---|
| Revenue | US$15.91b |
| Cost of Revenue | US$4.97b |
| Gross Profit | US$10.94b |
| Other Expenses | US$9.15b |
| Earnings | US$1.79b |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | 1.22 |
| Gross Margin | 68.74% |
| Net Profit Margin | 11.27% |
| Debt/Equity Ratio | 51.9% |
How did B1SX34 perform over the long term?
See historical performance and comparison